Latest news

BerGenBio pivots and merges with radiopharma firm Oncoinvent after drug failure

BerGenBio pivots and merges with radiopharma firm Oncoinvent after drug failure

Joachim Eeckhout
Argenx inks $1.5B deal with Unnatural Products for oral peptide drugs

Argenx inks $1.5B deal with Unnatural Products for oral peptide drugs

Joachim Eeckhout
Amgen’s FGFR2b drug shows survival boost in phase 3 gastric cancer trial

Amgen’s FGFR2b drug shows survival boost in phase 3 gastric cancer trial

Joachim Eeckhout
AbbVie bets big on next-gen CAR-T with $2.1B Capstan buyout

AbbVie bets big on next-gen CAR-T with $2.1B Capstan buyout

Joachim Eeckhout
FDA eases restrictions on CAR-T cancer therapies

FDA eases restrictions on CAR-T cancer therapies

Joachim Eeckhout
Alphabet’s Calico inks $596M deal for anti-aging antibody

Alphabet’s Calico inks $596M deal for anti-aging antibody

Joachim Eeckhout
Novartis bets $750M on ProFound's next-gen heart drugs

Novartis bets $750M on ProFound's next-gen heart drugs

Joachim Eeckhout
Vor pivots to autoimmune drugs and brings in new CEO

Vor pivots to autoimmune drugs and brings in new CEO

Joachim Eeckhout
Bayer-owned BlueRock cuts staff and shift strategy

Bayer-owned BlueRock cuts staff and shift strategy

Joachim Eeckhout
Molecular glue biotech Kymera signs with Gilead and updates Sanofi deal

Molecular glue biotech Kymera signs with Gilead and updates Sanofi deal

Joachim Eeckhout
RNA heart drug spinout to launch with $40M

RNA heart drug spinout to launch with $40M

Joachim Eeckhout
Chinese biotechs are catching up with the GLP-1 craze

Chinese biotechs are catching up with the GLP-1 craze

Joachim Eeckhout
FirstBack
123
Next Last